Resultats de la cerca - Shebl, Amgad

  • Mostrar 1 - 6 resultats de 6
Refinar resultats
  1. 1
    Anti‐A/B isoagglutinin reduction in an intravenous immunoglobulin product and risk of hemolytic anemia: a hospital‐based cohort study

    Anti‐A/B isoagglutinin reduction in an intravenous immunoglobulin product and risk of hemolytic anemia: a hospital‐based cohort study per Wallenhorst, Christopher, Patel, Ami, Shebl, Amgad, Hubsch, Alphonse, Simon, Toby L., Martinez, Carlos

    Publicat 2020
    Obtenir text complet Obtenir text complet Obtenir text complet
    Text
    Afegir a favorits
    Guardat en:
  2. 2
    Impact of screening and exclusion of high anti‐A titer donors on the risk of hemolytic anemia with intravenous immunoglobulin treatment: A hospital‐based cohort study in the US

    Impact of screening and exclusion of high anti‐A titer donors on the risk of hemolytic anemia with intravenous immunoglobulin treatment: A hospital‐based cohort study in the US per Martinez, Carlos, Watson, Douglas J., Shebl, Amgad, Wallenhorst, Christopher, Hubsch, Alphonse, Simon, Toby L.

    Publicat 2017
    Obtenir text complet Obtenir text complet Obtenir text complet
    Text
    Afegir a favorits
    Guardat en:
  3. 3
    Isoagglutinin reduction in intravenous immunoglobulin (IgPro10, Privigen) by specific immunoaffinity chromatography reduces its reporting rates of hemolytic reactions: an analysis of spontaneous adverse event reports

    Isoagglutinin reduction in intravenous immunoglobulin (IgPro10, Privigen) by specific immunoaffinity chromatography reduces its reporting rates of hemolytic reactions: an analysis... per Shebl, Amgad, Gabriel, Susie, Van Dinther, Kristy, Hubsch, Alphonse, Lawo, John‐Philip, Hoefferer, Liane, Welsh, Susan

    Publicat 2020
    Obtenir text complet Obtenir text complet Obtenir text complet
    Text
    Afegir a favorits
    Guardat en:
  4. 4
    Safety of biweekly α(1)-antitrypsin treatment in the RAPID programme

    Safety of biweekly α(1)-antitrypsin treatment in the RAPID programme per Greulich, Timm, Chlumsky, Jan, Wencker, Marion, Vit, Oliver, Fries, Michael, Chung, Thomas, Shebl, Amgad, Vogelmeier, Claus, Chapman, Kenneth R., McElvaney, Noel G.

    Publicat 2018
    Obtenir text complet Obtenir text complet Obtenir text complet
    Text
    Afegir a favorits
    Guardat en:
  5. 5
    Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study)

    Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA stu... per Léger, Jean-Marc, De Bleecker, Jan L, Sommer, Claudia, Robberecht, Wim, Saarela, Mika, Kamienowski, Jerzy, Stelmasiak, Zbigniew, Mielke, Orell, Tackenberg, Björn, Shebl, Amgad, Bauhofer, Artur, Zenker, Othmar, Merkies, Ingemar S J

    Publicat 2013
    Obtenir text complet Obtenir text complet Obtenir text complet
    Text
    Afegir a favorits
    Guardat en:
  6. 6
    Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneuropathy And Treatment with Hizentra study

    Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneur... per Mielke, Orell, Bril, Vera, Cornblath, David R., Lawo, John‐Philip, van Geloven, Nan, Hartung, Hans‐Peter, Lewis, Richard A., Merkies, Ingemar S.J., Sobue, Gen, Durn, Billie, Shebl, Amgad, van Schaik, Ivo N.

    Publicat 2019
    Obtenir text complet Obtenir text complet Obtenir text complet
    Text
    Afegir a favorits
    Guardat en:

Eines de cerca: